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HEPATITIS B VIRUS AND HEPATITIS A VIRUS IN KINGSTON, JAMAICA: 
MATERNAL-CHILD IMMUNITY. Jennifer Lee Hirsh and Francis L. Black, 
Department of Epidemiology and Public Health, Yale University, School of Medicine, 
New Haven, CT. 
This study was performed on women and their infants in Kingston, Jamaica to 
assess the impact of Hepatitis B Virus and Hepatitis A Virus in this developing country. 
Serological assays for disease-related antigens and antibodies were performed for 
epidemiological evaluation. Age-specific prevalences as well as persistence of passive 
immunity were among the items considered. The prevalence of Hepatitis B Virus 
antigenemia in the population studied in Kingston, Jamaica, is comparatively low (0.33 
percent) with respect to other geographical regions. Analagous findings include a low 
rate of vertical transmission of Hepatitis B surface Antigen (zero percent), and a low 
prevalence rate of Antibody to Hepatitis B core in individuals who lack Antibody to 
Hepatitis B surface Antigen (1.0 percent). Evidence of maternally-derived, passively- 
acquired immunity to Hepatitis B surface Antigen can be demonstrated as persisting in 
40 percent of infants at an average of 6.2 months of age. The overall prevalence of 
Antibody to Hepatitis A Virus is 74.6 percent, indicating that by child bearing age, at 
least 75 percent of the population have been infected. The age-specific distribution may 
either reflect accumulated exposure to Hepatitis A Virus, or may reflect increasing 
hygienic and socioeconomic standards. Ironically, this may in fact leave the country 
subject to more apparent hepatitis than some countries where children have been 
infected with Hepatitis A Virus early in life. Antibodies to Hepatitis A Vims in 
neonates are maternally-derived, as opposed to having arisen as a response to acute 
infection. Early infection in homes where the mothers have been infected does not pose 
a special risk. The prevalence of such passively acquired antibodies to Hepatitis A 
Vims is high (58.3 percent) and is most likely a result of high initial titers. As a 
developing country, Jamaica has been able to exact considerable control over infections 




Viral hepatitis is an infection which involves the liver, and four types of 
etiologic agents have been classified: 1) Hepatitis A Virus (HAV) 2) Hepatitis B Virus 
(HBV) 3) non-A non-B Hepatitis agents, and 4) the Delta agent, associated 
concommitantly with HBV. The delta agent is implicated only in the presence of HBV, 
and as of present, there is no serologic antigenic determinant of non-A non-B Hepatitis. 
Therefore, in assessing the role of viral hepatitis in Jamaica, only the impact of 
Hepatitis A and Hepatitis B on women and their infants of the Caribbean island of 
Jamaica was studied. 
Jamaica 
The island of Jamaica encompasses an area of 4,244 square miles. Across it are 
approximately 2,388,000 inhabitants, 578,000 of whom live in Kingston, the nation's 
capital. The literacy rate is 86 percent, and the life expectancy 71 years. The economy 
is supported in part by the bauxite industry, but recently the demand for bauxite has 
decreased, and tourism has become an increasingly important source of income. Other 
export products include coffee, sugar, bananas, and, unofficially, marijuana. The per 
capita income is $1300.15 
Although the tourist's perception of Jamaica is that of clear, azure waters off of 
white sand beaches, the "land of wood and water", as it was called by its first 
inhabitants, the Arawak, is not all that simple. Fifty percent of the island's population 
is under the age of twenty, and unemployment remains a large problem.15 Various 
"settlement" areas exist within Kingston, where houses are made of concrete and 
corrugated zinc; "yards" are partitioned by fences made of flattened gasoline cans; and 
chickens, goats, and children scamper underfoot. These houses have no running 
water, although water is available at centrally located stations within the settlement. 
Forty-six percent of the population live in the urban areas, which amount to a mere 5.5 
percent of the island's area.15 The influx of previously rural dwellers has strained the 
urban public resources. Not all of Kingston, however, is ghetto. The city is home to 
the dance, theater, and music of Jamaica. The fruits of the land and the wares of the 
people abound in the marketplace. And Kingston is the location of the University 
Hospital of the West Indies, which contains major medical facilities as well as the 




Hepatitis A Virus (HAV) is a non-enveloped single-stranded RNA virus which 
possesses most of the features of a picomavirus, of which enterovirus is a main 
subdivision.22 HAV can be inactivated by ultraviolet radiation, exposure to 
formaldehyde and chlorine, or by boiling for one minute. It appears that all strains of 
the virus are of one serotype and are antigenically indistinguishable. Antibodies to 
HAV (Anti-HAV) present early in the disease are of the IgM class; these peak within a 
few weeks. During convalescence, the IgG class predominates.41 After acute hepatitis 
illness, Anti-HAV protects the individual from becoming reinfected.7 The mode of 
transmission of HAV is primarily via the fecal-oral route,51 thus the prevalence of HAV 
infection is an index of the adequacy of sanitary practices. Although water-borne or 
food- borne epidemics have been noted, spread of the disease is most often due to 
person-to-person contact.51 This occurs as the virus is shed in the fecal material of the 
infected individual and is transferred to the mouth of another individual, as may occur 
in conditions of close contact and/or poor hygiene.24 HAV is transferred from the 
gastrointestinal tract to the liver, and there, primary replication ensues. The virus is 
passed into feces via the biliary system.46 Humans are the only natural 
epidemiologically important host of HAV.41 Distribution of the virus is worldwide, 
based on serological data.46-51 The age distribution of those infected is related to the 
level of endemicity of HAV and also the status and rate of change of the 
socioeconomic, hygienic, and housing conditions of the recent decades.46 Anti-HAV 
prevalence has been shown to be related to socioeconomic level, community size, and 
overcrowded housing conditions.47 Viral shedding in feces has been demonstrated two 
to three weeks prior to the onset of illness, as marked by jaundice, and for 8 to 10 days 
afterward.24 In developed countries, improvements in sanitation and socio-economic 
conditions have contributed to a decline in the incidence of HAV.7 No conclusive 
evidence for a HAV-c airier state exists,19*41 but Anti-HAV serves as a serologic 
marker for previous HAV infection.7 In the general United States population, the 
prevalence of Anti-HAV increases with increasing age and decreasing socioeconomic 
status. In developing countries, HAV infection and the immunity that follows occur 
predominantly in childhood.7 In some countries with high HAV prevalence, nearly 
100 percent of the individuals become infected and then develop immunity by the age of 
ten.24 Perpetuation of HAV is related to population density, level of sanitation and 
hygiene, and socioeconomic conditions.46 
4 

Hepatitis B Virus 
Hepatitis B Virus (HBV) is a partly-double stranded DNA virus. The virion, 
also known as the Dane particle, contains a circular DNA molecule.57 The virion is 
comprised of an outer coat and an inner icosahedral nucleocapsid core. Hepatitis B 
surface Antigen (HBsAg), originally referred to as Australia antigen, is present in the 
outer coat, and is comprised mainly of two major polypeptides.7 Various HBsAg 
subdeterminants have been identified. The common group-reactive antigen is 
shared by all HBsAg isolates. Subtype-specific antigens, d or y, w or r, may also be 
present The subtype does not affect the clinical course of the disease, but does serve 
as a marker for epidemiologic studies.41 Hepatits B core Antigen (HBcAg) is present 
on the nucleocapsid core. HBsAg and HBcAg do not cross react. Hepatitis B e 
Antigen (HBeAg) is found only in HBsAg-positive serum. 
The course of HBV infection can be followed by the antigenic markers that 
appear at various times. HBsAg appears first and is detectable for approximately one to 
two months after icterus appears. After the clearance of HBsAg, actively acquired 
antibodies to HBs (Anti-HBs) can be detected, at which time resolution of the diseases 
occurs; however, about 5-15% of infected patients fail to make antibody to HBsAg 
during convalescence.41 Anti-HBs continues to persist in most persons after infection 
and is thought to be the protective antibody.7 HBsAg has been identified in nearly 
every bodily fluid, but the most common route of transmission is percutaneous via 
blood. Other non-percutaneous routes include intimate (especially sexual) contact and 
perinatal transmission.20-41 
Hepatitis B core Antigen (HBcAg) is not usually detected in patients with HBV 
infection because the HBcAg is sequestered within the HBsAg coat.7 Antibodies 
against HBcAg (Anti-HBc), however, are detectable from approximately one to two 
weeks after HBsAg is detected. Anti-HBc is also present weeks to months before Anti- 
HBs can be detected. Occasionally, there is a temporal gap between the time HBsAg is 
cleared and the time that Anti-HBs appears. During this time, the only serologic marker 
of HBV infection may be Anti-HBc.45 IgG Anti-HBc may remain detectable for many 
years after infection27-61 In chronic infection, IgM Anti-HBc titers may indicate the 
level of virus activity. On the other hand, low titers of only IgG Anti-HBc without 




Hepatitis B e Antigen (HBeAg) is found in temporal association with HBsAg. 
HBeAg also is associated with high levels of viral replication and represents circulating 
intact virions, DNA polymerase, and HBV DNA.7 In self-limited HBV infections, 
Anti-HBe becomes detectable; this is associated with a lower level of viral infectivity. 
In protracted infections, HBeAg may persist, marking replicative infection with 
detectable specific DNA polymerase; this is a time of maximal infectivity. In chronic 
HBV infection, Anti-HBe is usually detectable whereas HBeAg is not; this disease 
state is often non-replicative. 
Clinical Course of Acute Hepatitis Infection 
Initial prodromal symptoms include anorexia, nausea, vomiting, fatigue, 
malaise, arthralgias, myalgias, headache, pharyngitis, cough, and coryza. Fever of 
100 -102°F may also occur. Once jaundice sets in, the prodromal symptoms usually 
diminish. The prodrome of Hepatitis B is often more insidious than that of Hepatitis 
A.41 The liver becomes enlarged and tender, resulting in right upper quadrant pain and 
tenderness. Liver function test results show an increase in the serum 
aminotransferases, SGOT and SGPT, as well as an elevation in bilirubin. These 
elevations tend to be more prolonged in Hepatitis B.41 In the case of extensive 
hepatocellular necrosis, the prothrombin time may become elevated, reflecting a defect 
in hepatic synthesis of the enzymes of the clotting cascade. Initial neutropenia and 
lymphopenia precede a relative lynphocytosis. Complete recovery, both clinically and 
with regards to laboratory test values, usually occurs after one to two months after 
Hepatitis A and after three to four months in 75 percent of uncomplicated cases of 
Hepatitis B.7 Laboratory values may normalize later in the remainder. Acute Hepatitis 
A is generally a self-limited disease, with fulminant hepatic failure rarely occurring 49 
However, complicated courses may ensue in those of advanced age or with 
underlying medical problems, such as diabetes mellitus or congestive heart failure. The 
case fatality rate in Hepatitis A and B is approximately 0.1 percent, but the fatality rate 
is one percent in those ill enough to be hospitalized for Hepatitis B 7 Although HAV 
has been implicated as the main etiologic agent of fulminant hepatitis in Chilean 
children,68 Hepatitis B is responsible for more than fifty percent of fulminant hepatitis, 
also known as massive hepatic necrosis, in the general population.7 In this dreaded 
complication, patients usually present with encephalopathy and may progress to coma. 
The combination of hepatic failure and encephalopathy may be evidenced by rapidly 
shrinking liver, elevated prothrombin time and bilirubin levels, ascites, edema, 
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confusion, and disorientation. Cerebral edema is common. Fatal sequelae include 
brainstem compression, gastrointestinal bleeding, sepsis, respiratory failure, 
cardiovascular collapse, and renal failure.7 
Approximately 5-10 percent of infected patients may never clear HBsAg from 
their circulation,23 and are termed HBsAg carriers. There is an increased incidence of 
HBsAg carriers after HBV infection in neonates, homosexual males, and the 
immunocompromised individual.41 HBsAg-positive individuals may 1) be 
asymptomatic 2) have low-grade chronic persistent hepatitis, or 3) have chronic active 
hepatitis. HBsAg-carriers also have an increased incidence of cirrhosis and 
hepatocellular carcinoma (HCC). Evidence for this includes both correlation between 
geographic distribution of HCC and HBsAg, as well as increased frequency of 
detection of HBsAg in individuals with HCC.58 In the United States and Western 
Europe, hepatocellular carcinoma comprises only 2 to 2.5 percent of malignant tumors 
discovered at autopsy, yet in parts of Africa and Asia, it may comprise 20 to 40 percent 
of malignancies.58 During the course of HBV infection, the viral genome becomes 
integrated into that of the host. Clones of these hepatocytes are the basis of malignant 
transformation.55 The number of persistent carriers in the world, as estimated by 
seroepidemiological surveys, is now more than 200 million.23 HCC is a fatal disease, 
and most patients die within three to six months of gastrointestinal hemorrhage, hepatic 
failure, or cachexia.7 Delta hepatitis virus superimposed on chronic Hepatitis B can 
worsen the severity of the latter, even to the point of development of fulminant 
hepatitis. HAY does not appear to progress to chronic liver disease.41 
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Materials and Methods 
Maternal serum collection from 304 women was performed at the University 
Hospital of the West Indies in Kingston, Jamaica between July 11, 1986 and August 
18, 1986. These accounted for approximately 85 percent of all deliveries during that 
time period. A few omissions were because of seriously complicated births, and a few 
were because the women declined to participate, but most omissions represented 
problems getting to the patients while they were in the hospital. The women were 
representative of a broad socio-economic spectrum from all parts of the city and 
surrounding rural areas; however, they represented a more than usually health-aware 
population in that a stipulation for admission was initiation of pre-natal care within six 
weeks of gestation. The ages of the mothers ranged from 16 to 44 years, with a mean 
of 26.0 years. After written consent was obtained, 10 mL of maternal blood was 
obtained by venipuncture. The whole blood was allowed to clot. Blood samples were 
then centrifuged at 1000 rpm for 10 minutes. The serum from each sample was 
removed with a Pasteur pipette. Serum samples were stored in 5 mL aliquots and kept 
frozen in a refrigerator freezing unit for approximately three days, until they could be 
placed in a -40° F freezer. Serum samples were kept frozen and were transported on 
dry ice from Kingston, Jamaica back to New Haven, Connecticut, where they were 
stored in a -40°F freezer. On one occasion, serum samples were noted to be thawed 
between transfer from the best available freezer to the -40° F degree freezer at the 
University Hospital of the West Indies. 
Concommitant placental cord blood samples were obtained, using a 10 mL 
syringe and 19 gauge needle. When placental cord blood was obtained at night, the 
blood was refrigerated in a glass VacutainerTM tube morning, when it was 
centrifuged. Centrifugation, serum separation, and storage of placental cord samples 
were as per the protocol for the maternal samples. 
Between December 1986 and January 1987, blood samples from 222 infants of 
mothers in the study were obtained by venipuncture. The 145 infants not bled were 
omitted because of a rural address outside the geographic range for home visit (51%), 
inability to locate the home (31%), failed venipuncture (12%), refusal of permission 
(4%), or death of the infant (2%). The mean age at the time of venipuncture was 186.6 
days. (6.2 months) 
In July of 1987, the serum samples were assayed for 1) Hepatitis B surface 
Antigen (HBsAg) 2) Antibody to Hepatitis B surface Antigen (Anti-HBs) 3) Antibody 
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to Hepatitis B core Antigen (Anti-HBc) 4) Antibody to Hepatitis A virus (Anti-HAV) 
and 5) IgM Antibody to Hepatitis A virus (IgM Anti-HAV) in the following manner. 
Hepatitis B surface Antigen (HBsAg) 
All 304 maternal samples were assayed for Hepatitis B surface Antigen. Those 
maternal samples that were positive for the antigen had assays performed for the 
detection of antigen in matched cord and infant sera, when available. For detection of 
Hepatitis B surface Antigen, the Riausure E^M radioimmunoassay from Electro- 
Nucleonics Inc. was used. The test was based on the "sandwich" technique. To each 
tube with a glass particle containing Antibody to Hepatitis B surface Antigen (goat), 0.2 
mL of patient serum was added. Each set of 90 patient serum samples was run with 
three positive and seven negative controls. Incubation for 1 hour was performed in 
which 24 cycles of sample agitation and settling on the RiausureTM Auto Processor 
occurred. Any Hepatitis B surface Antigen present in the serum being tested would 
combine with the Antibody to Hepatitis B surface Antigen (goat). 1.0 mL of 0.01 M 
phosphate buffer (sodium salts) and 0.15 M NaCl in double distilled water was added 
to each of the tubes. A single cycle of sample washing (60 seconds agitation and 90 
seconds settling) was performed and the contents of each tube aspirated, allowing for 
3-4 mm above the glass particle. 0.1 mL of 125j labelled antibody to Hepatitis B 
surface Antigen was added to each tube. Incubation for 1 hour was performed, in 
which 24 cycles of sample agitation and settling occurred. Contents of each tube were 
aspirated, allowing for 3-4 mm above the glass particle. Four cycles of sample 
washing (60 seconds agitation and 90 seconds settling) with 1.0 mL of 0.01 M 
phosphate buffer followed by aspiration were performed. Within 24 hours of 
completing the assay, radioactivity of each sample was counted in a Packard Auto 
Gamma 5650 gamma scintillation counter for one minute. 
Antibody to Hepatitis B surface Antigen (Anti-HBs) 
Two-hundred five maternal serum samples, negative for HBsAg, were assayed 
for antibody to Hepatitis B surface Antigen, using AUSAB^M radioimmunoassay from 
Abbott Laboratories. The samples were selected by criterion of adequate volume of 
serum but were otherwise felt to be an accurate representation of the population studied. 
Those maternal samples that were positive for the antibody had subsequent assays 
performed for the detection of antibody in the infant's serum, when available. 
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Seven negative and three positive controls were run with each batch of 90 
patient serum samples. One polystyrene bead coated with Hepatitis B surface Antigen 
was added to each well of a reaction tray. 200 microliters of serum and positive and 
negative controls were added to the respective reaction tray wells. Reaction trays were 
tapped to ensure complete distribution of liquid over the polystyrene beads. Reaction 
trays were covered and incubation at room temperature for 18 hours was performed. 
The contents of the wells were aspirated and each bead was washed in the following 
manner. A Pasteur pipette attached to a vacuum source was placed next to the bead and 
the liquid was aspirated from each well. 4 mL of double distilled water was added to 
the well two times, for a total rinse volume of 8 mL, while simultaneously aspirating 
the wash solution. Each bead was released from the pipette vacuum at least once 
during the wash cycle to assure even washing of the bead surface. 
At this point, any antibody to Hepatitis B surface Antigen that was present in 
the patient serum sample, would be bound to the polystyrene bead containing Hepatitis 
B surface Antigen. 200 microliters of 125i Hepatitis B surface Antigen was then added 
to each reaction well. Reaction wells were tapped to ensure that the radioactively 
labelled antigen solution completely surrounded the polystyrene beads. Reaction trays 
were covered and incubation for 4 hours at room temperature took place. The liquid 
solution from each well was aspirated and each polystyrene bead was again washed in 
the manner previously described. The beads were transferred from their reaction tray 
wells to assay tubes and were then placed in a Packard Auto Gamma 5650 gamma 
scintillation counter. Within 24 hours of completing the assay, radioactivity of each 
sample and control was counted for one minute. 
Antibody to Hepatitis B core Antigen (Anti-HBc) 
Ninety-five maternal serum samples, negative for Anti-HBs, were assayed for 
the detection of antibody to Hepatitis B core Antigen. These 95 samples were 
randomly selected except for the one sample known to be HBs-Antigen-positive. The 
decision not to assay the rest of the samples was based on the results of the first 95, 
that showed no other Anti-HBc-positivity except in the HBsAg-positive sample. Thus 
it was unlikely that HBsAg had been cleared, but Anti-HBs had not yet appeared in our 
sera. The CORAB^M assay from Abbott Laboratories was employed. This assay is 
based on the principle of competitive inhibition, in which non-radioactive antibodies to 
Hepatitis B Core from serum samples compete with a constant amount of radioactive 
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antibody to Hepatitis B Core for a limited number of binding sites on beads coated with 
Hepatitis B core Antigen. 
100 microliters of 125j labelled Antibody to Hepatitis B core Antigen was 
added to each well of a reaction tray. 100 microliters of patient serum sample or 
controls (three negative and two positive controls) were then added. The reaction tray 
was tapped vigorously to ensure thorough mixing of reaction components. One bead 
containing Hepatitis B core Antigen was then added to each well. The reaction trays 
were covered and incubated at room temperature for 20 hours. The liquid contents of 
each well were then aspirated and the beads washed three times with 4 mL of double 
distilled water for a total rinse volume of 12 mL. The beads were then transferred to 
assay tubes and the radioactivity counted in a Packard Auto Gamma 5650 gamma 
scintillation counter for one minute. Controls and unknowns were counted together 
within 24 hours of completing the assay. 
Antibody to Hepatitis A Virus (Anti-HAVl 
Two-hundred one maternal samples were assayed for antibody to Hepatitis A. 
The samples were selected by criterion of adequate volume of serum, but were 
otherwise felt to be an accurate representation of the population studied. Those 
maternal samples that were positive for the antibody had assays performed on the 
paired infant's serum, when available. The HAVAB^M radioimmunoassay by Abbott 
Laboratories was employed. This assay is based on the principle of competitive 
inhibition, in which antibodies to Hepatitis A in the patient's serum compete with 
radioactively labelled antibodies to Hepatitis A, for Hepatitis A Virus that is coated on a 
bead. 
10 microliters of patient serum sample or control serum (three negative and two 
positive controls) were placed in the wells of the reaction trays. 200 microliters of 125j 
antibody to Hepatitis A Virus was added to each well. One Hepatitis A Virus coated 
bead was then placed in each well containing a control or serum sample. Each reaction 
tray was covered and tapped to remove any trapped air bubbles. Reaction trays were 
incubated at room temperature for 18 hours. The covers were then removed from the 
trays and the liquid contents of each well were aspirated. Each bead was washed two 
times with 4 mL of double distilled water for a total rinse volume of 8 mL. The beads 
were then transferred to counting tubes, and within 24 hours, the radioactivity of each 




IgM Antibody to Hepatitis A Virus (IgM Anti-HAV) 
Forty-five infant samples that were positive for antibody to Hepatitis A Virus 
were assayed for IgM specific for Hepatitis A Virus. These infant samples were 
selected at random from the 84 Anti-HAV-positive infant samples and were felt to be an 
accurate representation of the population. The HAVAB-M^M assay from Abbott 
Laboratories was employed. Specimens were diluted 1:200 with 0.15 M normal saline 
in glass tubes and vortexed gently to ensure mixing. 10 microliters of positive control 
or negative control or diluted specimen was pipetted into each well. 200 microliters of 
specimen diluent was added to each well, and trays were tapped to mix contents. One 
bead, coated with Antibody to Human IgM, was added to each well. Specimens were 
incubated at room temperature for 2 hours. The liquid was aspirated from each well, 
and each bead was washed twice with 4.5 mL double distilled water for a total rinse 
volume of 9 mL. 200 microliters of Hepatitis A Virus (Human) was added to each well 
containing a bead. Specimens were incubated at room temperature for 22 hours. 
Liquid was aspirated from each well and again each bead was washed twice with 4.5 
mL double distilled water for a total rinse volume of 9.0 mL. 200 microliters Anti- 
HAV 125i Was pipetted into each well with a bead, and specimens were incubated in a 
45° C water bath for 4 hours. Liquid was aspirated and each bead washed with 4.5 
mL double distilled water for a total rinse volume of 9.0 mL. Beads were transferred to 
properly identified counting tubes and immediately placed in a Packard Auto Gamma 




Assay for Hepatitis B surface Antigen (HBsAg) 
The radioimmunoassay RIAUSURE^M ,Electro-Nucleonics Inc., is based on 
the sandwich technique. If HBsAg is present in the serum sample, it will bind to 
Antibody to HBsAg (Anti-HBs) coated on the bead placed in each well. In turn, 
labelled Antibody to HBsAg (125j Anti-HBs) will bind to the HBsAg already bound to 
the beads, forming an antibody-antigen-antibody "sandwich". (See Figure 1) In this 
manner, the amount of radioactivity detected will be directly proportional to the HBsAg 
in any serum sample. The appropriate cutoff value was determined as outlined in the 
RIAUSURE B™ manual. (See Appendix VI) Only one of the 304 maternal samples 
tested (0.33%) had a count-per-minute (cpm) value well above that of the cutoff value, 
and was therefore considered to be positive for Hepatitis B surface Antigen. The 
mother from whom the sample was taken was 23 years old and lived in a rural area 
outside of Kingston proper. The matched cord sample had a count-per-minute value 
that was just above the cutoff value, and was considered to be weakly positive for 
HBsAg. The matched infant sample, taken at 199 days of age, was negative. 
Assay for Antibody to Hepatitis B surface Antigen (Anti-HBs) 
The radioimmunoassay AUSAB^M, Abbott Laboratories, is also based on die 
sandwich technique. Polystyrene beads coated with Hepatitis B surface Antigen 
(HBsAg) are exposed to serum samples which may contain antibody to Hepatitis B 
surface Antigen (Anti-HBs). Any Anti-HBs present will bind to the HBsAg on the 
bead. In turn, Hepatitis B surface Antigen (125j_HBsAg) is added and 
wil bind to any Anti-HBs already bound to the polystyrene bead, forming an antigen- 
antibody-antigen "sandwich". (See Figure 2). In this manner, the amount of 
radioactivity present will be directly proportional to the amount of Anti-HBs in each 
sample. The appropriate cutoff value was determined as outlined in the AUSAB^M 
manual. (See Appendix VII). Thirty-three of the 205 maternal samples (16.1%) had 
cpm values greater than the cutoff value and were therefore considered positive for 
Anti-HBs. When results were grouped according to maternal age, 4 of 37 (11%) of 
16-20 year olds were positive for Anti-HBs; 12 of 73 (16%) of 21-25 year olds; 11 of 
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60 (18%) of 26-30 year olds; 5 of 31 (16%) of 31-40 year olds were positive for Anti- 
HBs. (See Table 1) Of these maternal samples that tested positive, twenty of the 
matched infant sera were tested. Eight of the 20 (40%) infant samples had values 
greater than the cutoff value and were therefore considered positive for Anti-HBs. 
Antibody to Hepatitis B core Antigen (Anti-HBcl 
The CORABTM assay, Abbott Laboratories, is a competitive 
radioimmunoassay. Any Anti-HBc present in serum samples competes with a constant 
amount of Anti-HBc for a limited number of binding sites on beads that 
are coated with Hepatitis B core Antigen (HBcAg). In this manner, the amount of 
radioactivity detected is inversely proportional to the amount of Anti-HBc in any given 
serum sample. The appropriate cutoff value was determined as outlined in the 
CORABTM manual. (See Appendix VIII). Only one of the 95 maternal serum 
samples had a cpm value that was less than the cutoff value, and was therefore 
considered to be positive for Anti-HBc. Of note, this was the same sample that was 
positive for HBsAg, suggesting that the subject may have had an acute concurrent 
infection. 
Antibody to Hepatitis A Virus 
The HAVABTM radioimmunoassay, Abbott Laboratories, is a 
competitive binding assay in which any Anti-HAV in a serum sample competes with 
i^I-labelled Anti-HAV for binding sites on a bead coated with Hepatitis A Virus 
(HAV). In this manner, the amount of radioactivity detected will be inversely 
proportional to the amount of Anti-HAV in any given serum sample. The appropriate 
cutoff value was determined as outlined in the HAVAB^M manual. (See Appendix IX) 
One-hundred fifty of the 201 (74.6%) maternal serum samples tested had cpm values 
less than or equal to that of the cutoff value and were therefore considered positive for 
Anti-HAV. One-hundred forty-four serum samples from infants of mothers positive 
for Anti-HAV were tested. Eighty-four of those 144 (58.3%) infant sera samples 
tested positive for Anti-HAV. 
When results were grouped according to maternal age, 24 of 33 (73%) of 16-20 
year-olds were positive for Anti-HAV; 49 of 76 (64%) of 21-25 year-olds; 47 of 63 
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(75%) of 26-30 year-olds; 30 of 39 (77%) of 31-40 year-olds were positive for Anti- 
HAV. 
(See Table 2). 
IgM Antibody to Hepatitis A Virus (IgM Anti-HAV) 
The HAVAB-MTM radioimmunoassay, Abbott Laboratories, is based on the 
"sandwich" technique. Beads coated with Antibody to Human IgM bind to any 
available IgM in a given serum sample. Hepatitis A Virus (HAV) is then added; Only 
if the IgM that is already bound to the bead is directed against HAV, will IgM bind 
HAV. Next, 125i Anti-HAV is added and can bind to any HAV already bound in 
earlier steps. (See Figure 3). In this manner, the amount of radioactivity detected will 
be directly proportional to the amount of IgM directed specifically against HAV in any 
given serum sample. The appropriate cutoff value was determined as outlined in the 
HAVAB-MTM manual. (See Appendix X). Forty-five infant samples that were 
previously found positive for Anti-HAV, were tested for IgM antibody directed against 





Hepatitis B surface Antigen 
Maternal Sera Hepatitis B surface Antigen; 
The Jamaican sera reveal only one of the 304 (0.33 percent) of maternal 
samples as positive for Hepatitis B surface Antigen (HBsAg). The chronic carrier rate 
for HBsAg has been estimated as 0.1-0.2 percent in Britain, the United States, and 
Scandanavia; 3 percent in Greece and Southern Italy; and 10-15 percent in Africa and 
the Far East.55 Other estimates of the HBsAg chronic carrier rate are 0.1-0.5 percent in 
Europe, North America, and Australia; 5 percent in Southern and Eastern Europe and 
Central and South America; 5-10 percent in the Middle East; and up to 20 percent in 
some parts of Africa, Asia, and the Pacific.23 By comparison, the 0.33 percent HBsAg 
prevalence in Jamaican sera is relatively low. The persistent carrier state has been 
defined as HBs antigenemia for greater than 6 months.41 Therefore, this one Jamaican 
sample that is HBsAg positive may either represent acute Hepatitis or chronic Hepatitis 
B carriage. Determination would require further serologic marker studies. High titer 
IgM Anti-HBc would indicate acute Hepatitis B whereas low titer would indicate 
chronic Hepatitis B. IgG Anti-HBc would also indicate chronic Hepatitis B 
infection.55 In any event, it appears that the carrier rate of HBsAg in the population 
studied in Jamaica is less than or equal to 0.33 percent. In such low HBsAg prevalence 
areas, inoculation of blood continues to be a major mode of of spread, such as via 
surgical and dental procedures, intravenous drug abuse, tattooing, acupuncture, and 
laboratory accidents, as well as communally utilized razors and tooth brushes.41*69 
Others at risk of transmission in low incidence areas include patients on hemodialysis, 
blood product recipients, residents in institutions for the mentally handicapped, 
prisoners, male homosexuals, and the sexually promiscuous.23 These aforementioned 
risks are most likely the mode of transmission in Jamaica, where the prevalence of 
Hepatitis B Virus antigenemia is low. 
Cord and Infant Sera Hepatitis B surface Antigen: 
In the Jamaican study, the only umbilical cord sample that was HBsAg- 
positive, was that matched to the HBsAg-positive maternal sample. The matched infant 
sample, taken at 199 days (6.6 months) of age, was HBsAg-negative. There is some 
controversy regarding antigenemia in umbilical cord blood. Some researchers believe 
that HBsAg can be transmitted across the placenta, but others doubt its true presence 
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and consider it a result of contamination.54 It has also been demonstrated that in 
patients routinely screened during pregnancy, levels of maternal Anti-HBs and cord 
Anti-HBs are comparable, whereas HBsAg is much less easily detectable in cord blood 
as compared to maternal blood.54 It has therefore been postulated that antibody to HBV 
crosses the placental barrier more easily than does the antigen itself, thus first allowing 
passive immunization of the fetus in early or mid-gestation and then subsequent 
prevention of the disease in utero. 54 Other studies to evaluate prevention of perinatal 
transmission have considered infants whose cord blood is HBsAg-positive to have had 
intra-uterine infection.34 If we are to believe that HBsAg found in cord blood is not 
merely a contaminant, then these studies may partially explain why only some of the 
infants whose cord blood is HBsAg-positive go on to develop Hepatitis B antigenemia: 
passive immunization provides protection against HBV infection after exposure to 
maternal HBsAg. 
Vertical transmission is defined as the transmission of Hepatitis B Virus from 
mother to infant.54 The first observations of "vertical" or "maternal-child" transmission 
of HBV were made in 1972, when familial clustering of HBsAg was noted.43 In this 
project, they studied a group of sisters, all of whom were HBsAg-positive. Among 
them, they had 24 offspring, 20 of whom were HBsAg-positive (83 percent HBsAg- 
positivity). Then they studied a group of brothers, all of whom were HBsAg-positive. 
Among them, they had 7 offspring, only 1 of whom was HBsAg-positive (14 percent 
HBsAg-positivity). This indicated that maternal-child transmission was the mode of 
infection. Another fact that supported vertical transmission, was that the one HBsAg- 
positive child of the brothers, was bom to a mother who had Anti-HBs, indicating that 
she had been previously infected and could have vertically transmitted the HBV 
infection to her child. Within each family, there was only one subtype of HBV.43 It 
has been observed that HBsAg-positive cord blood is not a useful criterion for defining 
HBV infection in the infant, because infection often could not be confirmed on follow¬ 
up serological studies of the child,57 as in our case. However, the presence of HBsAg 
in the infant's umbilical cord blood has been shown to be a risk factor in the 
development of HBsAg-positivity in the infant.56 In Taiwan, it was observed that 76 
percent of infants with HBsAg-positive cord bloods became HBsAg-positive, whereas 
only 35 percent of infants with HBsAg-negative cord bloods became HBsAg-positive 
by two months of age.56 Other related risk factors in the development of infant 
antigenemia include titer of HBsAg, as determined by complement fixation, and 
HBsAg-positivity in siblings.56 Indeed, HBsAg in cord blood is not the only factor 
influencing vertical transmission of HBV: a study on the maternal-child transmission of 
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HBsAg in four ethnic groups in Britain revealed similar proportions of HBsAg 
positivity in the cord bloods of the various groups, but vertical transmission was 
significantly higher in the Chinese.18 Other studies have conclusively demonstrated the 
importance of the maternal Hepatitis B e Antigen in vertical transmission of 
HBsAg.4’23’42 Eighty-five percent of infants whose mothers were HBeAg-positive 
became HBsAg-positive, versus 31 percent of infants whose mothers were HBeAg- 
negative. The mean length of follow-up time was 12 months for all infants. The 
presence of maternal HBeAg has also been correlated with maternal HBsAg titer, as 
determined by complement fixation,4 and with HBsAg-positivity in the infant's 
siblings,4 a factor previously shown to be a risk factor for the development of HB V 
antigenemia in the infant.53 A decreasing pattern of perinatal transmission may be seen 
in areas where improved sanitation and a decrease in number of household members 
has occurred 42 Among Japanese women, one of the most important factors is the 
capability to convert from a HBeAg-positive to a HBeAg-negative state before reaching 
reproductive age. Because dietary protein has been considered to be of primary 
importance in immunological competence, it has been postulated that increased protein 
comsumption may be responsible for the decrease in HBeAg-positivity.42 
Hepatitis B Virus is believed to be causally associated with the development of 
Hepatocellular Carcinoma (HCC) by the following chain of events: 1) exposure to 
HBV leads to 2) induction of the HBsAg-carrier state, leads to 3) chronic hepatitis, 
leads to 4) cirrhosis, leads finally to 5) hepatocellular carcinoma.58 Evidence to 
support the causal relationship between HBV and HCC include a close correlation in 
the geographic distribution of HCC and HBV, particularly with chronic HBs- 
antigenemia.58 Also, HBsAg is detectable with unusually high frequence in HCC 
patients.58 Between 60 and 90 percent of all HCC patients have concurrent cirrhosis, 
implying that cirrhosis may be an important factor in the development of HCC.58 
There is convincing evidence that vertical transmission of HBV occurs much more 
frequently in regions of high- incidence HCC than in low-incidence regions.4’54-56 
This is related to the frequence of HBeAg-positivity in HBsAg-carriers 4’44 In HCC 
high-incidence areas, the patients with HCC are on average much younger than HCC 
patients in low-incidence areas. One possible explanation is that exposure to the 
etiologic agent occurs earlier in life in the high-incidence areas,58 such as via maternal- 
child transmission. Age at which primary HBV infection occurs enhances the 
probability of becoming a HBsAg-carrier. Ninety-five percent of those infected 
perinatally become chronic carriers, versus fewer than 10 percent of those infected as 
adults.53 Because the mortality of hepatocellular carcinoma is virtually 100 percent and 
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because in certain countries it is the most common cancer in young men, the impact of 
HCC is significant, and therefore related factors, such as vertical transmission of the 
Hepatitis B Virus, are important. 
Vertically acquired HB V infection is usually anicteric and is recognized by the 
appearance of HBsAg between 60 and 120 days after birth.41 The mechanism of 
infection is uncertain, although it probably involves ingestion or inadvertent inoculation 
of maternal blood by the infant during passage through the birth canal.41 The 
frequency of vertical transmission of Hepatitis B Virus to infants from HBsAg-carrier 
mothers varies throughout different parts of the world. Studies in Denmark and 
Thailand have estimated the HBV vertical transmission rate from HBsAg-positive 
mothers as zero percent, whereas that in Greece was 6.5 percent, in the United States 
was 16.5 percent, and in Taiwan was 40 percent.54 These geographic differences may 
be attributed to a number of factors, including maternal HBsAg titer,54 presence of 
Anti-HBe,44 and type of early postpartum care and the degree of physical intimacy 
between mother and infant during the neonatal period.54 Antigenemia in the infant 
usually develops by the time the infant is 6 months of age. One study demonstrated 
that 51 of 63 (81 percent) infants bom to HBsAg-positive mothers became HBsAg- 
positive by 6 months of age.56 In addition, children who develop antigenemia early on 
in life, between two and four months, become persistent HBsAg-camers,41 and it is 
known that persistent HBsAg-carriers are at greater risk for hepatocellular carcinoma.58 
In contrast to this, most children who become HBsAg-positive later in life have been 
shown to lose antigenemia within 6 months of becoming HBsAg-posititive 48 
Our data show that one Jamaican cord blood sample was HBsAg-positive. It is 
possible that the sample represents intra-uterine infection, with passive immunization of 
the infant in utero and subsequent prevention of HBV infection. However, the count- 
per-minute rate was just barely above the cutoff value, and a more likely explanation is 
contamination of the cord sample with maternal serum. The infant bom to the HBsAg- 
positive mother had not developed HBV antigenemia by 199 days (6.6 months) of life. 
Since maternal-child transmission by HBsAg-positive mothers occurs in 81 percent of 
infants by six months of age, the Jamaican infant will most likely not develop HBV 
antigenemia. According to previous studies,48 even in the event that antigenemia does 
occur in this 6.6 month old infant, it is not likely to persist. It would appear that the 
prevalence of Hepatitis B surface Antigen in Jamaica is relatively low, and maternal- 
child transmission is not a dominant mode of infection. 
Antibody to Hepatitis B surface Antigen (Anti-HBs); 
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In the Jamaican data, 33 of 205 (16.1 percent) of maternal samples were 
positive for Anti-HBs, indicating that infection had occurred in these individuals. The 
serologic evidence of current or past infection varies according to geography. The 
prevalence of Antibody to Hepatitis B has been estimated at 7-10 percent in the United 
States and Western Europe; 20-50 percent in South America, Southeast Europe, and 
North Africa; 60-80 percent in Africa and Southeast Asia, and virtually 100 percent in 
the Pacific Islands.46 Other estimates of Anti-HBs are 3-5 percent in Switzerland and 
Belgium; 11 percent in the United States; 15 percent in Israel; 34 percent in Yugoslavia; 
62 percent in Senegal; and 78 percent in Taiwan.60 By comparison, the prevalence of 
Anti-HBs in the Jamaican population studied is at the lower end of the prevalence 
spectrum. Hygienic conditions and socioeconomic levels have both been shown to be 
inversely proportional to the prevalence of HBV infection.46 Relatively high standards 
in Jamaica may be partially responsible for the lower Anti-HBs prevalence seen in the 
Kingston population. 
Age Distribution of Hepatitis B Infection: 
The age distribution for Hepatitis B infection depends on the level of endemicity 
of the virus in addition to socioeconomic and hygienic standards and cultural factors.46 
Exposure to HBV at an early age is related to degree of intrafamial contact, 
socioeconomic and hygienic conditions, and medical standards.46 These factors all 
influence the percutaneous inoculation rate of infectious blood and secretions 46 The 
exact mechanism of intrafamilial transmission has not been defined.24 
Studies done in the Pacific Islands show evidence that the prevalence of HBV 
markers increases with age, peaking at about 40 years of age.25 In Ethiopia, the 
prevalence of Anti-HBs was shown to be higher in those over the age of 15 years than 
in the younger age groups.65 Papaevangelou reports that prevalence of serologic 
evidence of past or current infection rises with increasing age throughout life with a rate 
that depends on the endemicity of HBV infection 46 
The age distribution of the Jamaican data indicate a rise in prevalence of Anti- 
HBs with increasing maternal age. (See Figure 4). It appears that a steady prevalence 
level is reached by approximately 30 years of age, indicating that most infection occurs 
prior to 30 years. Thus, there is no continuous increase in Anti-HBs prevalence 
throughout life in this population, signifying a lack of continuous exposure to HBV 
over the course of a lifetime. This attests to the relatively high socioeconomic and 
hygienic standards of Kingston, which effectively limit the spread of the disease. 
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Anti-HBs: Infant Sera 
"Passive Immunization" of the fetus occurs as immunoglobulins of the IgG 
subclass, antibodies, are transported from the maternal circulation to that of the fetus. 
These IgG molecules reflect various infectious agents to which the mother has been 
previously exposed. In the newborn infant at time of birth, levels of immunoglobulin 
are similar to those of the mother. There is virtually no immunoglobulin of the IgA or 
IgM subclass because the fetus is protected from antigenic stimulus in uiero. However, 
if infection occurs, the fetus will respond with antibody production, mainly of the IgM 
type. Passively transferred IgG has a half-life of 30 to 40 days, and immunoglobulin 
concentration decreases with the first few months of life; the lowest levels occur 
between two and four months of age.5 This decline is due to both dilution by infant 
growth, and catabolic degredation.52 Maternally derived antibodies are considered to 
be protective against HBV for the first 6 months of an infant’s life.65 
In the Jamaican study, mothers who would be able to transfer Anti-HBs to their 
infants would need to be Anti-HBs-positive themselves. In this group of women, 
twenty matched infant samples were available for analysis. Eight of the 20 samples 
assayed (40 percent) were Anti-HBs-positive at an average ofl87 days (6.2 months) of 
age. This duration of maternally acquired immunity to HBV is similar to that of 
immunity to measles in Jamaica, as assessed by hemeagglutination-inhibition.14 
Measles antibody half-life in these children was found to be only slightly shorter than 
that observed in more developed regions. 
Given the low HBsAg prevalence rate found in Jamaica, it would seem that the 
Anti-HBs seen in infants at 6.2 months of age is antibody that is passively acquired 
from the mother, not antibody synthesized by the infant in response to infection. 
Therefore, maternally acquired immunity is present in 40 percent of infants at 
approximately 6.2 months of age. IgM studies in these children would confirm this but 
were not carried out for reason of cost. 
Antibody to Hepatitis B core (Anti-HBc) 
The Jamaican sera that were Anti-HBs-negative were assayed for Anti-HBc. In 
this manner, assessment could be made of any individuals who had cleared HBsAg but 
had not yet demonstrated Anti-HBs. Because of the nature of the assay, any class of 
Antibody to Hepatitis B core, be it IgG or IgM, would be able to compete with 
radioactively labelled Anti-HBc for binding sites to the HBcAg-coated bead. IgM Anti- 
HBc indicates the acutely infected, highly infectious patient.55 Persistent IgM Anti- 
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HBc indicates ongoing HBV chronic hepatitis.55 IgG Anti-HBc in the presence of 
Anti-HBs signals clinical or subclinical HBV infection in the remote past.55 IgG Anti- 
HBc in the absence of Anti-HBs indicates persistent viral infection.55 The CORAB™ 
assay was used as an Anti-HBc survey; further classification of immunoglobulin type 
could be made if necessary, pending the results of the Anti-HBc survey. The Jamie an 
sera demonstrated only one sample that was positive for Anti-HBc. This sample was 
from the same individual who was HBsAg-positive. It is thus most likely that the Anti- 
HBc detected was of the IgM class of immunoglobulins and represented an acutely 
infected, highly infectious individual. No other Anti-HBc-positive samples were found 
in the group of Anti-HBs-negative samples studied, indicating lack of evidence of 
persistent HBV infection in the population. This is consistent with earlier results 
showing the low prevalence of HBsAg in the population. The very low prevalence of 
Anti-HBc in the absence of Anti-HBs, and the low HBsAg prevalence rate, indicate that 
persistent HBV infection or HBV-carriage is infrequent in the population studied in 
Jamaica. 
Antibody to Hepatitis A Virus (Anti-HAV) 
Maternal Sera; 
One hundred-fifty of the 201 (74.6 percent) samples studied were Anti-HA V- 
positive. The prevalence of Anti-HAV varies with geography. Estimates of Anti-HAV 
prevalence are 29 percent in Switzerland,60 34 percent in Ethiopia,65 44 percent in the 
United States,60 76 percent in Senegal,60 81 percent in Belgium,60 82 percent in 
Nigeria,3 87 percent in Spain,9 89 percent in Taiwan,60 95 percent in Israel,60 97 
percent in Yugoslavia,60 and 100 percent in Namibia/SouthWest Africa33 and the 
Pacific Islands.67 Prevalence of exposure to HAV in various regions of the world is 
considered to be a function of hygienic and developmental factors,19 which are of 
utmost important in the fecal-oral spread of the disease.60 Such environmental and 
socioeconomic conditions, however, are not the only influencing factors. In Belgium, 
for instance, standards of living are similar to those in Switzerland and the United 
States; the Anti-HAV prevalence, however, was two to four times that of the other two 
countries.60 In general, overall prevalence of Anti-HAV in Jamaica is lower than that 
of other developing countries and even lower than that of a few developed countries. 
This low level of Anti-HAV-positivity reflects the efficacy of the Kingston water and 
sewage systems since the primary mode of transmission of the disease if fecal-oral. As 
in other studies,8-9>19.26.31.36,67 t^e prevalence of Anti-HAV increased with increasing 
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age. (See Figure 5) Three major age-specific prevalence patterns have been described 
for Anti-HAV.24 In the first pattern, rapid acquisition of Anti-HAV occurs early in life, 
and most individuals become infected by 10 years of age. This pattern is seen in most 
developing countries, where the spread of enteric viruses is facilitated by the prevailing 
standards of sanitation and hygiene. The second pattern is that of increasing prevalence 
of Anti-HAV with increasing age. This pattern occurs in most developed countries and 
urban populations and demonstrates a steady decline in the incidence of infection over 
the past three or four decades, as a result of improving standards of sanitation and 
hygiene. The third age-specific prevalence pattern is relatively rare, in which an 
epidemic of HAV occurs and the virus spreads until all susceptible individuals have 
contracted the disease. Having exhausted its supply, the virus then dies out. A high 
prevalence of Anti-HAV is detected among those individuals alive at the time of the 
outbreak; no antibody is detected among those bom subsequent to it.24 The age- 
specific prevalence pattern seen in Jamaica is that of increasing prevalence of Anti-HAV 
with increasing age, the pattern seen in most developing countries that have experienced 
recent advances in hygiene and sanitation. This pattern may be interpreted in two 
ways. First, the increasing prevalence with increasing age could represent continuous 
exposure to HAV throughout the lifetime of the individual. In this manner, there would 
be a cumulative effect of Anti-HAV prevalence in the older segments of the population. 
This interpretation, however, conflicts with the epidemiological data that show this 
prevalence pattern to occur in regions with recent advances in sanitation and hygiene. 
Another interpretation of this age-specific prevalence pattern is that the younger 
segments of the population have a lower Anti-HAV prevalence because of recent 
improvements in hygiene and sanitation. Before these improvements, an almost 
universally immune population was achieved at minimal cost by natural HAV 
infections.30 Ironically, this situation creates an interesting dilemna. Hepatitis A Virus 
infection is commonly asymptomatic or at least relatively mild in young children, but as 
the age of infection increases, so does clinical severity.41 As the risk of HAV infection 
continues to decline for younger children, a large suseptible population may result, 
providing ample opportunity for future epidemics in young adults.30*41 Therefore 
although the prevalence patterns of HAV infection reflect improvements in conditions 
of hygiene and socioeconomic standards in Jamaica, future epidemics in a now- 




One-hundred forty-four samples were available for analysis from infants whose 
mothers were Anti-HAV-positive. Of these, 84 (58.3 percent) were Anti-HAV- 
positive. The average age at time of serum collection was 188 days (6.3 months). 
Although it is known that maternal antibodies protect infants up until 6 to 8 months of 
age, not all others studies have documented such a high prevalence rate of passively 
acquired Anti-HAV in infants. One study in Taiwan30 estimated the prevalence of 
maternally acquired Anti-HAV as 27 percent at less than one year of age. The estimate 
for Mexico was 33 percent.36 The frequency of passively acquired antibody against 
HAV in Jamaican infants was 58.3 percent. To determine whether these prevalence 
rates were true indicators of passive immunity or whether they instead represented 
neonatal infection, infant sera that were Anti-HAV-positive were assayed for Anti-HAV 
of the IgM subclass. Diagnosis of HAV infection is performed most reliably by 
determination of IgM-Anti-HAV.41 If the infant sample were Anti-HAV-positive but 
not IgM-Anti-HAV-positive, the antibody against HAV would presumably be of 
maternal origin. The assay for IgM-Anti-HAV revealed that none of the Anti-HAV- 
positive Jamaican infants tested were positive for IgM-Anti-HAV. Therefore the high 
prevalence of Anti-HAV seen in the Jamaican study was a reflection of persistent 
maternally acquired antibody, not acute HAV infection. A similar phenomenon of low 
prevalence Anti-HBs but high prevalence Anti-HAV in neonates has been reported in 
Taiwan.31 The differences in neonatal Anti-HBs and Anti-HAV prevalence are most 
likely due to a higher titer of maternally derived Anti-HAV. 
Conclusions: 
In summary, the prevalence of Hepatitis B Virus antigenemia in the population 
studied in Kingston, Jamaica, is comparatively low (0.33 percent) with respect to other 
geographical regions. Analagous findings include a low rate of vertical transmission of 
Hepatitis B surface Antigen (zero percent), and a low prevalence rate of Antibody to 
Hepatitis B core in Anti-HBs-negative individuals (1.0 percent). Evidence of 
maternally-derived passively-acquired immunity to Hepatitis B surface Antigen can be 
demonstrated as persisting in 40 percent of infants at an average of 6.2 months of age. 
The overall prevalence of Antibody to Hepatitis A Virus is 74.6 percent, indicating that 
by child bearing age, at least 75 percent have been infected. The age-specific 
distribution may either reflect accumulated exposure to Hepatitis A Virus, or may reflect 
increasing hygienic and socioeconomic standards, which, ironically, may in fact leave 
the country subject to more apparent hepatitis than some countries where children are 
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infected with HAV early in life. Antibodies to Hepatitis A Virus in neonates are 
maternally-derived, as opposed to arising as a response to acute infection. Early 
infection in homes where mothers have been infected does not pose a special risk. The 
prevalence of such passively acquired antibodies to Hepatitis A Virus is high (58.3 
percent) and is most likely a result of high initial titers. As a developing country, 
Jamaica has been able to exact considerable control over infections due to both Hepatitis 
B Virus and Hepatitis A Virus. 
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Table No. 1 
Anti-HBs (Maternal) 
Age Range Age;Weighted Mean_ No. (+)_N.Q, lasted_%1±) 
16-20 yrs 18.9 yrs 4 37 11 
21-25 yrs 23.0 yrs 12 73 16 
26-30 yrs 28.2 yrs 11 60 18 
31-40 yrs 33.8 yrs 5 31 16 
Aee Ranee 
Table No. 2 
Anti-HAV (Maternal) 
Aee:Weiehted Mean_No. (+)No. Tested % (+) 
16-20 yrs 18.7 yrs 24 33 73 
21-25 yrs 23.1 yrs 49 76 64 
26-30 yrs 28.1 yrs 47 63 75 































































I. Hepatitis B surface Antigen (HBsAg) Lot Nos. 
RIAIJSURE II™, Electro-Nucleonics Laboratories, Inc. 
Master Lot No. 1419, 1420, 1421 
125I Anti-HBs: 3901417 
CPG Tablet: 3906234 
Positive Control: 3903081 
Negative Control: 3902115 
Buffer: 3410002 
n. Antibody to Hepatitis B surface Antigen (Anti-HBs) Lot Nos. 
AUSAB™, Abbott Laboratories 
Maternal Samples 
Hepatitis B surface Antigen beads: 02499M103 
Positive Control: 01239BW00 
Negative Control: 01495BW03 
125I Anti-Hbs: 2968M103 
Infant Samples 
Hepatitis B surface Antigen beads: 03068M303 
Positive Control: 02625M302 
Negative Control: 03220M303 
125I Anti-HBs: 05920M103 
HI. Antibody to Hepatitis B core Lot Nos. 
CORAB™, Abbott Laboratories 
Master Lot No.: 06435M100 
Hepatitis B core Ag (rDNA) coated beads: 02387M202 
Positive Control: 03968M103 
Negative Control: 02506M302 
125I Anti-HBc: 05038M203 
IV. Antibody to Hepatitis A Lot Nos. 
HAVAB™, Abbott Laboratories 
Maternal Samples: 
Master Lot No.: 06142M100 
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Hepatitis A beads: 04881M103 
Positive Control: 04376M203 
Negative Control: 04377M203 
1251 Anti-HAV: 05579M102 
Infant Samples: 
Master Lot No.: 06769M100 
Hepatitis A beads: 04881M103 
Positive Control: 04376M203 
Negative Control: 04377M203 
1251 Anti-HAV: 05991M202 
V. IgM Antibody to Hepatitis A Lot Nos. 
HAVAB-M™, Abbott Laboratories 
Master Lot No.: 22591M100 
Positive Control: 18195M302 
Negative Control: 18223M203 
Ab to Human IgM coated beads: 18206M302 
Specimen diluent: 18176M302 
HAV: 19922M203 
1251 Anti-HAV: 21112M202 
VI. Calculation of Cutoff Value for Assay for HBsAg 
A. Mean value in counts per minute (cpm) of negative controls calculated by 
taking the average of the individual negative control values. 
B. Acceptable range for individual values of negative controls is 
(0.5-1.5) times the mean. All samples must be re-run if more than one result 
is outside this range. 
C. Mean value (in cpm) of positive controls is calculated by taking 
the average of the individual positive control values. 
D. Positive Control Mean divided by Negative Control Mean must be 
greater than 5 for test data to be valid. 
E. Cutoff Value=[Negative Control Mean (cpm)-Background (cpm)] X2 + 
background (cpm). 
All specimens which are greater than this value must be 
considered reactive for HBsAg. 
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VH. Calculation of Cutoff Value for Assay for Anti-HBs. 
A. Negative Control Mean (in cpm) is calculated by taking the 
average of the individual negative control values. 
B. Elimination of one (or no) aberrant values of negative controls 
1. Each value must lie within the range of (0.5-1.5) times the 
negative control mean. 
2. If more than one value lies outside this range, technique 
problems should be investigated. 
C. Positive Control Mean (in cpm) is calculated by taking the 
average of the individual positive control values. 
D. Positive Control Mean divided by Negative Control Mean 
must be greater than or equal to 15.0 for technique to be 
acceptable and data considered valid. 
E. Cutoff Value = (Negative Control Mean - Background) X 2.1 
+ Background. Samples with gross count rates greater than this value are 
considered to be reactive with respect to Anti-HBs. 
Vm. Calculation of Cutoff Value for Assay for Anti-HBc 
A. Negative Control Mean (in cpm) is calculated by subtracting background 
radiation from individual negative control values and then taking the average 
of the net values. 
B. Elimination of one (or no) aberrant values of negative controls: 
1. Each value must lie within the range of (0.5-1.5) times the 
negative control mean. 
2. If more than one value lies outside this range, technique problems 
should be investigated. 
3. If one value is outside this range, it is rejected as aberrant, and the 
negative control mean is recalculated. 
C. Positive Control Mean (in cpm) is calculated by subtracting the background 
radiation from individual positive control values and taking the average of 
those net values. 
D. Check the validity of each run: Negative Control Mean divided by Positive 
Control Mean must be greater than 5 to ensure the validity of each run. 
E. Determination of Cutoff Value: 
Cutoff Value = (Negative Control Mean + Positive Control Mean) / 2 + 
background radiation. Samples with cpm values less than or equal to the 
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cutoff value are considered reactive with respect to Anti-HBc by 
criteria of the CORAB™ test. 
IX. Calculation of Cutoff Value for Assay for Anti-HAV. 
A. Negative Control Mean (in cpm) is calculated by subtracting background 
radiation from individual negative control values and then taking the average 
of those net values. 
B. Positive Control Mean (in cpm) is calculated by subtracting background 
radiation from individual positive control values and then taking the average 
of those net values. 
C. Ensuring the validity of each run: Negative Control Mean divided by 
Positive Control Mean must be greater than 5 to ensure the validity of each 
run. 
D. Cutoff Value = (Negative Control Mean + Positive Control Mean)/2 + 
background. Samples with cpm values which are less than or equal to the 
cutoff value are considered reactive with respect to Anti-HAV. 
X. Calculation of Cutoff Value for Anti-HAV (IgM) 
A. Negative Control Mean (in cpm) is calculated by subtracting background 
radiation from individual negative control values and then taking the average 
of those net values. 
B. Positive Control Mean (in cpm) is calculated by subtracting background 
radiation from individual positive control values and then taking the avaerage 
of those net values. 
C. Elimination of aberrant values: Individual Positive Control values should lie 
within the range of (0.5-1.5) times the Mean Positive Control value. 
1. If one positive control sample lies outside this range, it is 
rejected as aberrant and a revised mean positive control 
value is calculated. 
2. If more than one value is consistently outside the range, 
technique problems should be investigated. 
D. Ensuring the validity of each run: Positive Control Mean divided by 
Negative Control Mean must be greater than 5.0 to ensure the validity of 
each run. 




1. Specimens with cpm values less than the cutoff value are 
non-reactive by criteria of the test. 
2. Specimens with cpm values repeatably greater than or 
equal to the cutoff value are positive by criteria of the test 
3. Specimens within +10% of the cutoff value should be 
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